Macrosalb Medi-Radiopharma (Macrosalb (99mtc))

The product contains macroaggregated albumin particles that are chemically bound to technetium‑99m, a gamma‑emitting radionuclide. After intravenous injection, the particles lodge in the small capillaries of the lungs. A gamma camera then detects the emitted radiation, producing images that reflect the pattern of pulmonary blood flow and highlighting any perfusion defects.

The prescribed activity is determined by the ordering physician based on the specific imaging protocol, patient size, and clinical indication. Dosing is individualized and follows established nuclear medicine guidelines; the product label provides preparation instructions but does not specify a fixed dose.

Safety in pregnancy and lactation has not been definitively established. The radiopharmaceutical should be used only when the expected diagnostic benefit outweighs the potential radiation risk to the fetus or infant. Clinicians should discuss possible risks with the patient and consider alternative imaging methods when appropriate.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if needed) and any required import documentation.

Macrosalb (macroaggregated albumin 99mTc) is the standard agent for lung perfusion imaging. Alternative agents, such as other brands of technetium‑99m macroaggregated albumin, offer similar particle size and imaging characteristics. Non‑radioactive alternatives do not provide functional perfusion data, making macroaggregated albumin the preferred choice for accurate pulmonary embolism detection and pre‑operative assessment.

The kit should be stored refrigerated at 2‑8 °C, protected from light, and must not be frozen or shaken. It should remain in its original sealed container until reconstitution. After preparation, the solution should be used promptly according to the manufacturer’s instructions and any unused portion discarded in accordance with local radiopharmaceutical waste regulations.

Macrosalb is supplied as a lyophilized powder that is reconstituted with a sterile diluent immediately before use. The reconstituted solution is injected intravenously, typically through a peripheral vein, under the supervision of qualified nuclear medicine personnel. Proper aseptic technique and adherence to the preparation protocol are essential to ensure safety and image quality.

Serious adverse events, although rare, include pulmonary hypertension, severe allergic reactions such as anaphylaxis, and embolic complications from large particle aggregates. Patients should be monitored closely after injection for any signs of respiratory distress, hypotension, or allergic response, and emergency equipment should be readily available.

The product should be avoided in patients with known severe pulmonary hypertension, right‑heart failure, or a documented hypersensitivity to albumin or technetium‑99m compounds. It is also contraindicated in individuals for whom the radiation exposure is deemed unacceptable, such as certain pregnant women, unless the diagnostic benefit clearly outweighs the risk.